Heart Palpitations on Mounjaro: What the Evidence Shows

What the trial data and official guidance actually recorded

The SURMOUNT programme, which involved thousands of adults across its obesity trials, collected detailed safety data at every dose level. Palpitations were recorded in those datasets and appear in the Mounjaro Summary of Product Characteristics on the eMC under uncommon side effects — meaning they occurred in fewer than one in a hundred participants but more than one in a thousand. That classification puts them well below the GI effects (nausea, diarrhoea, constipation) that are described as common or very common, but it is not negligible either. It is worth understanding that clinical trials measure effects at a population level: individual experiences vary, and some people taking Mounjaro notice a fluttering or racing sensation in the chest that the trial averages do not fully capture. If you are curious about the broader relationship between tirzepatide and the heart, the evidence on how tirzepatide affects the heart covers the cardiovascular data in more depth.

The NHS tirzepatide medicines page lists palpitations as a side effect to be aware of, placing them alongside other less common effects that patients should monitor rather than dismiss. That framing is useful: awareness, not alarm.

Why palpitations might happen on Mounjaro

There is no single confirmed cause, which is why the research language stays careful. Two plausible pathways come up repeatedly in clinical discussion. The first involves dehydration. When nausea, vomiting or diarrhoea are significant in the first weeks of treatment or after a dose increase, fluid loss can reduce blood volume and trigger a faster, sometimes irregular, heartbeat. Palpitations that arrive alongside gut symptoms and ease as hydration is restored often fall into this category. Staying well hydrated during any period of GI upset is not optional — it is part of looking after yourself on this treatment.

The second pathway relates to GLP-1 receptor activity itself. GLP-1 receptors are found in cardiac tissue, and GLP-1 receptor agonists have a mild, direct effect on heart rate. Modest increases in resting heart rate have been observed in semaglutide trials; tirzepatide's dual mechanism introduces GIP receptor activity as well, and the net cardiac effect continues to be studied. This is one reason changes in resting heart rate on Mounjaro are worth understanding separately from palpitations, even though the two can overlap. People who want a broader picture of how the medicine interacts with the cardiovascular system may find the clinical overview of Mounjaro and the heart a useful read alongside this page, and our dedicated page on Mounjaro and heart health explores that evidence in further detail.

When palpitations need more than watchful waiting

A brief flutter after your first injection, or a racing sensation on the day your dose increases, is a different clinical situation from palpitations that are frequent, prolonged, painful or paired with other symptoms. Seek medical attention promptly if palpitations come with chest tightness or pain, breathlessness, dizziness, fainting, or a sense that your heart rhythm feels seriously disordered. These combinations may signal something that needs assessment beyond the expected profile of a GLP-1 medicine. Similarly, persistent palpitations that do not settle within a couple of weeks, or that worsen rather than improve, should be discussed with your prescriber rather than managed through patience alone.

Anyone who notices severe, persistent stomach pain radiating toward the back, with or without vomiting, should also seek urgent help: the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and the symptom profile can sometimes be confused with general GI discomfort. Suspected side effects from Mounjaro, including palpitations, can be reported at the MHRA's Yellow Card scheme, patient reports genuinely inform post-market safety monitoring for newer medicines like this one.

Practical steps while you are on treatment

If palpitations appear early in your treatment, keep a brief log: time of day, duration, whether you had eaten or drunk recently, whether you were dehydrated. That detail is genuinely useful for a prescriber trying to work out the likely cause. Alcohol can contribute to palpitations in its own right, and some people find the combination of GI effects and alcohol more disruptive than either alone, the guidance on alcohol while taking Mounjaro is worth a look if that is relevant to you.

Timing your injection may also matter. Some people find weekend injections convenient, while others notice that if they order around a bank holiday or their dose increase falls mid-holiday, the first day or two of adjustment land at an awkward moment. Planning ahead for those windows means you are not dealing with new symptoms in an unfamiliar place. Our prescribers are available for aftercare seven days a week through our support team, which is partly why we structure the service around ongoing access rather than a one-off prescription. For a fuller picture of the medicine's overall evidence base, the Mounjaro overview covers mechanism, eligibility and the broader trial programme.

If you are considering starting treatment and want to discuss your cardiovascular history as part of the assessment, a free consultation with our clinical team is the right first step. A GPhC-registered prescriber reads your answers the same day.